{"id":"NCT02493452","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)","officialTitle":"Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06","primaryCompletion":"2016-11","completion":"2017-02","firstPosted":"2015-07-09","resultsPosted":"2019-06-14","lastUpdate":"2019-06-14"},"enrollment":1135,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Irritable Bowel Syndrome Characterized by Constipation"],"interventions":[{"type":"DRUG","name":"Plecanatide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"3.0 mg plecanatide","type":"ACTIVE_COMPARATOR"},{"label":"6.0 mg plecanatide","type":"ACTIVE_COMPARATOR"},{"label":"Matching placebo","type":"ACTIVE_COMPARATOR"}],"summary":"This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.","primaryOutcome":{"measure":"Number of Overall Responders - ITT Population","timeFrame":"12 weeks","effectByArm":[{"arm":"Matching Placebo","deltaMin":54,"sd":null},{"arm":"3.0 mg Plecanatide","deltaMin":81,"sd":null},{"arm":"6.0 mg Plecanatide","deltaMin":91,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":12},"locations":{"siteCount":191,"countries":["United States"]},"refs":{"pmids":["32660770"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":376},"commonTop":["Diarrhea","Headache"]}}